Tag:

Achillion Pharmaceuticals

Latest Headlines

Latest Headlines

Achillion shares crushed in a rout as hep C blockbuster hopes fade

After the market closed on Friday, Achillion spread the word that the FDA is maintaining its clinical hold related to its once-hot hepatitis C drug sovaprevir, while distributing some unimpressive data on its combination approach.

Achillion shares skid lower after FDA puts a hold on hep C drug

Shares of Achillion skidded down 20% as the news spread Monday evening that the FDA put a clinical hold on its hepatitis C drug sovaprevir after investigators flagged a spike in liver enzymes--a classic sign of toxicity--among a group of patients taking it in a combo treatment.

Bristol-Myers, Achillion, Idenix show progress with oral hepatitis C drugs

Bristol-Myers Squibb is staying in the chase to commercialize an all-oral regimen for hepatitis C, despite having to end development of one of its key weapons against the liver-damaging disease this summer because of serious adverse events in study patients.

Achillion heralds upbeat hepatitis C results as it rushes through Phase II

A year ago buzz about a potential Achillion buyout was all the rage as big biopharma rivals jostled for the inside track in a multibillion-dollar race through the clinic with next-gen hepatitis C therapies.

Achillion Pharma strikes deal to raise $41.8M as hep C results loom

Hepatitis C drug developer Achillion Pharmaceuticals expects to haul in proceeds of a $41.8 million sale of common stock to QVT Financial. And the funding comes ahead of some important clinical trial results from the New Haven, CT-based developer's pipeline of hep C treatments.

Achillion Pharma attracts buyout buzz as hep C rivals fall

With developers of oral hepatitis C drugs falling hard in recent weeks, Achillion Pharmaceuticals has attracted fresh M&A speculation because the developer's contenders in this closely watched race remain unscathed in clinical studies.

Achillion burnishes buyout prospects, snags fast track for hep C drug

Achillion CEO Michael Kishbauch hasn't been the least bit shy about touting the company's buyout prospects. Quick to boast about the biotech's promising hepatitis C drugs, he's been raising hopes and stirring buyout buzz with every appearance.

Hep C drug deal frenzy can't be slowed by growing doubts

At the BIO CEO & Investor Conference in New York yesterday, Achillion CEO Michael Kishbauch wrapped up his remarks on the biotech's hepatitis C programs by making it clear that he was angling for

Idenix gets good news on hep C trial, but can't compete with Gilead

Idenix put out the news this morning that the FDA had lifted a partial hold on its hepatitis C drug IDX184--and then watched its share price slide. In a sign of just how volatile the whole hepatitis

Who's next on hep C biotech buyout hit list?

After the big biotech deal comes the big biotech buzz. And one of the big questions on everyone's mind after Gilead Sciences ($GILD) announced its $11 billion deal to acquire Pharmasset is, "Who's